ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2026 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of 9.190-9.690 for the period, compared to the consensus earnings per share estimate of 8.790. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Guggenheim raised their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Finally, Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 15th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP traded up $0.45 on Friday, hitting $84.36. 792,568 shares of the company’s stock were exchanged, compared to its average volume of 400,455. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19. The firm’s 50-day moving average price is $76.82 and its two-hundred day moving average price is $81.01. ANI Pharmaceuticals has a fifty-two week low of $56.71 and a fifty-two week high of $99.50. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of 25.09 and a beta of 0.46.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.97% and a net margin of 8.87%.The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. During the same quarter in the previous year, the firm posted $1.70 EPS. The firm’s quarterly revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts expect that ANI Pharmaceuticals will post 7.64 EPS for the current year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 5,323 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $78.02, for a total transaction of $415,300.46. Following the transaction, the insider owned 84,840 shares in the company, valued at approximately $6,619,216.80. The trade was a 5.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Thomas Andrew Rowland sold 4,772 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total value of $357,470.52. Following the transaction, the senior vice president owned 38,730 shares in the company, valued at $2,901,264.30. The trade was a 10.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 27,860 shares of company stock worth $2,111,581 in the last three months. 8.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. Kemnay Advisory Services Inc. purchased a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth approximately $48,000. State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $50,000. Tower Research Capital LLC TRC boosted its stake in shares of ANI Pharmaceuticals by 542.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,727 shares of the specialty pharmaceutical company’s stock worth $113,000 after acquiring an additional 1,458 shares in the last quarter. Finally, Maryland State Retirement & Pension System boosted its stake in shares of ANI Pharmaceuticals by 5.4% during the 4th quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after acquiring an additional 134 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.